INTRODUCTION {#s1}
============

Cervical cancer (CC) is one of the most common gynecologic cancers worldwide \[[@R1]\], with an estimated 527,600 new cases and 265,700 deaths each year \[[@R2]\]. The development of CC is considered as a continuous process from normal epithelium to squamous intra-epithelial lesion (SIL) and ultimately to invasive carcinoma \[[@R3]\]. SIL, the precursor lesions of CC, can be further divided into low-grade SIL (LSIL) and high-grade SIL (HSIL) depending on the risk of cancer progression \[[@R4]\]. Although infection with human papillomavirus (HPV) is a widely accepted risk factor for SIL and CC \[[@R5]\], the evidence that only a small subset of HPV-induced lesions progress to CC \[[@R6]\], suggests that HPV infection is essential but insufficient for cervical carcinogenesis \[[@R4]\].

DNA hypermethylation, the major epigenetic event in humans, can occur at CPG islands within promoter regions of tumor suppressor genes (TSGs), and consequently silence the TSGs\' transcription \[[@R7]\]. *P16^INK4a^* gene, a well known TSG, has been widely investigated in cervical cancer due to its downregulation in cell cycle \[[@R8]\]. Impaired *P16^INK4a^* gene function caused by promoter hypermethylation could result in uncontrolled cell proliferation and eventually oncogenesis \[[@R9]--[@R11]\]. In 1999, Wong et al. first reported that *P16^INK4a^* promoter hypermethylation was correlated with the advanced stage of CC \[[@R11]\]. Thereafter, numerous studies were carried out to assess the associations of *P16^INK4a^* hypermethylation with the development of SIL and CC. However, most of these studies only included relatively small sample size, leading to inconsistent results and a broad range of *P16^INK4a^* hypermethylation rates (from 2% to 93%) in cancer tissues \[[@R12], [@R13]\]. Moreover, the effect of *P16^INK4a^* promoter hypermethylation on different phases of cervical carcinogenesis (from LSIL to CC) is less summarized. Thus, a meta-analysis was conducted to systematically appraise the associations of *P16^INK4a^* methylation status with LSIL, HSIL, CC and their clinicopathological features.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

According to the definitions of the 2001 Bethesda System \[[@R14]\], LSIL encompassed cytopathic effects of HPV, mild dysplasia and cervical intraepithelial neoplasia (CIN) 1; HSIL contained moderate or severe dysplasia, carcinoma *in situ* (CIS) and CIN 2 or 3; CC encompassed squamous cell carcinoma (SCC) and adenocarcinoma (AdC). Based on these definitions, 43 articles were initially selected. Then, 19 articles were excluded due to *in vitro* experiments (*n* = 3), family-based designs (*n* = 2), abstracts (*n* = 2) or reviews (*n* = 8), non-English papers (*n* = 2) and insufficient data (*n* = 2). Manual search of references cited in the published articles identified four additional articles \[[@R15]--[@R18]\]. One article \[[@R19]\] contained data from two independent studies. Hence, 28 articles with 29 studies were finally included \[[@R11]--[@R13], [@R15]--[@R39]\]. Among these studies, all studies were eligible to estimate the *P16^INK4a^* hypermethylation rates; 20 studies (1 cross-sectional \[[@R13]\] and 19 case-control designs \[[@R16], [@R17], [@R19], [@R21]--[@R28], [@R30]--[@R35], [@R37], [@R38]\]) investigated the associations of *P16^INK4a^* methylation status with the risk of LSIL, HSIL and CC; 1254 SIL/CC patients from 18 studies (11 case-control studies \[[@R19], [@R21], [@R23], [@R25], [@R26], [@R31], [@R32], [@R35]--[@R38]\] and 7 case-only studies \[[@R11], [@R12], [@R15], [@R18], [@R20], [@R29], [@R39]\]) were eligible to assess the associations between *P16^INK4a^* methylation status and clinicopathological features. For most of these studies (26 studies), the methylation detection was based on methylation-specific PCR (MSP) (including MSP, nested MSP and MSP with another method (sequencing, prosequencing and BSP) for quality control). Only one study used plasma samples to detect methylation status \[[@R19]\]; other studies involved cervical tissues. Fifteen studies were conducted on Asians, 9 studies on Caucasians, 5 studies on other ethnicities (Brazilians, Moroccans and Senegalese). The flowchart for the study selection procedure was shown in Figure [1](#F1){ref-type="fig"}. The characteristics of included studies were summarized in Table [1](#T1){ref-type="table"}.

###### Characteristics of included studies in this meta-analysis

  No.   First author (Year)             Country   Ethnicity   Study design      Sample size   Methylation detection method   Materials   Source of controls   Involved clinicopathological features   Quality scores                                                                
  ----- ------------------------------- --------- ----------- ----------------- ------------- ------------------------------ ----------- -------------------- --------------------------------------- ---------------- ---- ------------------------------------------------------- ----
  1     Nakashima 1999 \[[@R20]\]       Japan     Asian       Case-only         \-            33                             \-          \-                   MSRE                                    Tissue           \-   Tumor type                                              12
  2     Wong 1999 \[[@R11]\]            China     Asian       Case-only         \-            98                             \-          \-                   MSP                                     Tissue           \-   FIGO stage, tumor grade, type                           10
  3     Dong 2001 \[[@R21]\]            Korea     Asian       Case-control      24            53                             \-          \-                   MSP and sequencing                      Tissue           B    Tumor grade, type, early age                            15
  4     Virmani 2001 \[[@R22]\]         USA       Caucasian   Case-control      22            19                             17          37                   MSP                                     Tissue           H    \-                                                      13
  5     Tsuda 2003 \[[@R15]\]           Japan     Asian       Case-only         \-            53                             33          9                    MSP                                     Tissue           B    HPV infection                                           13
  6     Gustafson 2004 \[[@R16]\]       USA       Caucasian   Case-control      11            \-                             17          11                   Nested MSP                              Tissue           H    \-                                                      11
  7     Lea 2004 \[[@R23]\]             USA       Caucasian   Case-control      78            60                             30          \-                   MSP                                     Tissue           H    FIGO stage, tumor grade, type, smoking, HPV infection   14
  8     Yang tissue 2004 \[[@R19]\]     China     Asian       Case-control      100           85                             \-          \-                   MSP and sequencing                      Tissue           A    FIGO stage, tumor grade, type                           13
  9     Yang plasma 2004 \[[@R19]\]     China     Asian       Case-control      30            40                             \-          \-                   MSP and sequencing                      Plasma           H    \-                                                      13
  10    Feng 2005 \[[@R17]\]            Senegal   African     Case-control      142           92                             46          39                   MSP                                     Tissue           M    \-                                                      10
  11    Kim 2005 \[[@R24]\]             Korea     Asian       Case-control      11            41                             19          11                   MSP                                     Tissue           B    \-                                                      11
  12    Lin 2005 \[[@R25]\]             Korea     Asian       Case-control      20            47                             10          20                   MSP                                     Tissue           B    Tumor type                                              11
  13    Jeong 2006 \[[@R26]\]           Korea     Asian       Case-control      24            78                             \-          \-                   MSP                                     Tissue           B    FIGO stage, tumor type, early age, smoking              15
  14    Kang 2006 \[[@R27]\]            Korea     Asian       Case-control      5             43                             7           31                   MSP and pyrosequencing                  Tissue           B    \-                                                      13
  15    Kekeeva 2006 \[[@R28]\]         Russia    Caucasian   Case-control      35            \-                             42          \-                   MSP                                     Tissue           H    \-                                                      10
  16    Yang 2006 \[[@R29]\]            China     Asian       Case-only         \-            127                            \-          \-                   MSP and sequencing                      Tissue           \-   FIGO stage, tumor grade, type                           12
  17    Ivanova 2006 \[[@R30]\]         Russia    Caucasian   Case-control      14            26                             \-          \-                   MSP and BSP                             Tissue           A    \-                                                      11
  18    Nehls 2008 \[[@R18]\]           Germany   Caucasian   Case-only         \-            70                             16          8                    Nested BSM-PCR                          Tissue           \-   HPV infection                                           12
  19    Attaleb 2009 \[[@R31]\]         Morocco   African     Case-control      20            22                             \-          \-                   MSP                                     Tissue           H    FIGO stage, tumor grade, HPV infection, early age       12
  20    Furtado 2010 \[[@R32]\]         Brazil    Brazilian   Case-control      20            \-                             27          \-                   MSP                                     Tissue           H    HPV infection                                           11
  21    Kim 2010 \[[@R33]\]             Korea     Asian       Case-control      41            69                             67          32                   Nested MSP                              Tissue           B    \-                                                      13
  22    Huang 2011 \[[@R34]\]           China     Asian       Case-control      15            26                             49          23                   MSP                                     Tissue           H    \-                                                      12
  23    Lof-Ohlin 2011 \[[@R12]\]       Sweden    Caucasian   Case-only         \-            109                            \-          \-                   Pyrosequencing                          Tissue           \-   \-                                                      11
  24    Spathis 2011 \[[@R35]\]         Greece    Caucasian   Case-control      41            12                             85          121                  MSP                                     Tissue           H    Tumor type                                              12
  25    Jha 2012 \[[@R36]\]             India     Asian       Case-control      100           125                            \-          \-                   MSP                                     Tissue           M    Smoking                                                 12
  26    Carestiato 2013 \[[@R13]\]      Brazil    Brazilian   Cross-sectional   28            29                             49          35                   MSP                                     Tissue           H    \-                                                      10
  27    Banzai 2014 \[[@R37]\]          Japan     Asian       Case-control      24            53                             22          \-                   MSP                                     Tissue           H    Tumor type                                              10
  28    Blanco-Luquin 2015 \[[@R38]\]   Spain     Caucasian   Case-control      13            67                             85          10                   MSP                                     Tissue           H    Tumor type                                              15
  29    Silveria 2015 \[[@R39]\]        Brazil    Brazilian   Cohort            \-            40                             \-          \-                   MSP                                     Tissue           \-   HPV infection                                           14

Abbreviation: CC, cervical cancer; LSIL, low-grade squamous intra-epithelial lesion; HSIL, high-grade squamous intra-epithelial lesion; MSRE, methylation-sensitive restriction endonucleases; MSP, methylation-specific PCR; BSP, bisculfite sequencing PCR; H, healthy controls; B, controls with benign gynecological diseases; A, autologous controls; M, mixed controls.

![Flowchart for the study selection procedures in this meta-analysis](oncotarget-08-1871-g001){#F1}

Pooled rates of *P16*^INK4a^ hypermethylation in patients with LSIL, HSIL and CC {#s2_2}
--------------------------------------------------------------------------------

A total of 388 LSIL \[[@R13], [@R15]--[@R18], [@R22], [@R24], [@R25], [@R27], [@R33]--[@R35], [@R38], [@R39]\], 636 HSIL \[[@R13], [@R15]--[@R18], [@R22]--[@R25], [@R27], [@R28], [@R32]--[@R35], [@R37], [@R38]\] and 1439 CC \[[@R11]--[@R13], [@R15], [@R17]--[@R26], [@R29]--[@R31], [@R33]--[@R38]\] specimens were included in this meta-analysis. As summarized in Table [2](#T2){ref-type="table"}, the pooled rates of *P16^INK4a^* hypermethylation showed an increasing trend (*p* \< 0.001 for the differences in pooled rates) from LSIL tissues (21.4%, 95% confidence interval (CI): 15.0-29.7%) to HSIL tissues (30.9%, 95% CI: 21.9-41.7%) and ultimately to CC specimens (35.0%, 95%CI: 27.6-43.3%). The respective *P16^INK4a^* hypermethylation rates for Asians and Caucasians were similar: 24.6% and 21.5% in LSIL tissues; 31.9% and 27.2% in HSIL tissues; 33.7% and 38.2% in CC specimens. In CC specimens, the pooled rates did not significantly change after excluding one study using plasma samples (35.6%, 95% CI: 28.0-44.1%).

###### Pooled hypermethylation rates of P16^*INK4a*^ in LSIL, HSIL and CC specimens

  Comparison   Studies (N)   Specimens (N)   Heterogeneity   Model [^a^](#tfn_001){ref-type="table-fn"}   Methylation rates (%)   
  ------------ ------------- --------------- --------------- -------------------------------------------- ----------------------- ------------------
  LSIL                                                                                                                            
  Total        14            388             47              0.025                                        R                       21.4 (15.0-29.7)
  Asian        6             86              21              0.278                                        F                       24.6 (16.1-35.5)
  Caucasian    5             193             67              0.016                                        R                       21.5 (9.8-41.0)
  Others       3             109             59              0.088                                        R                       13.8 (5.1-31.9)
  HSIL                                                                                                                            
  Total        17            636             82              \< 0.001                                     R                       30.9 (21.9-41.7)
  Asian        7             231             81              \< 0.001                                     R                       31.9 (18.2-49.7)
  Caucasian    7             286             76              \< 0.001                                     R                       27.2 (16.6-41.2)
  Others       3             119             88              \< 0.001                                     R                       34.5 (9.9-71.6)
  CC                                                                                                                              
  Total        24            1439            88              \< 0.001                                     R                       35.0 (27.6-43.3)
  Asian        14            941             87              \< 0.001                                     R                       33.7 (25.5-43.3)
  Caucasian    6             363             85              0.006                                        R                       38.2 (27.1-50.6)
  Others       3             135             96              \< 0.001                                     R                       39.7 (26.7-54.3)

When significant heterogeneity was found (I^2^≥ 50% or P~Q-test~ ≤ 0.1), the random-effects model (DerSimonian-Laird method) was used to pool the results; otherwise, the fixed-effects model (Mantel-Haenszel method) was applied.

Abbreviations: N, number; LSIL, low-grade squamous intra-epithelial lesion; HSIL, high-grade squamous intra-epithelial lesion; CC, cervical cancer; R, random-effects model.

Association of *P16*^INK4a^ methylation status with LSIL risk {#s2_3}
-------------------------------------------------------------

Eleven studies \[[@R13], [@R16], [@R17], [@R22], [@R24], [@R25], [@R27], [@R33]--[@R35], [@R38]\], involving 336 LSIL patients and 334 controls, were included to assess the association between *P16^INK4a^* methylation status and LSIL risk. Overall, *P16^INK4a^* promoter hypermethylation was associated with a 3.26-fold (95% CI: 1.86-5.71, *p* \< 0.001) increased risk of LSIL (Figure [2](#F2){ref-type="fig"} and Table [3](#T3){ref-type="table"}). This association remained significant in almost all subgroups, except for the "other ethnicities" subgroup (Table [3](#T3){ref-type="table"}). No significant heterogeneity was found in all comparisons (I^2^: 0-42%).

###### Pooled results for the association between ^*P16INK4a*^ promoter hypermethylation and LSIL risk

  Comparisons                                       Studies (N)   Sample size (LSIL/controls)   Heterogeneity   Model [^a^](#tfn_002){ref-type="table-fn"}   Effect size                       
  ------------------------------------------------- ------------- ----------------------------- --------------- -------------------------------------------- ------------- ------------------- ----------
  Total                                             11            336/334                       0               0.499                                        F             3.26 (1.86-5.71)    \< 0.001
  Ethnicity                                                                                                                                                                                    
  Asian                                             5             77/88                         0               0.817                                        F             7.76 (2.39-25.15)   0.001
  Caucasian                                         4             185/87                        4               0.374                                        F             2.98 (1.29-6.91)    0.011
  Other ethnicities                                 2             74/159                        42              0.190                                        F             1.39 (0.45-4.27)    0.565
  Source of controls                                                                                                                                                                           
  Healthy                                           6             237/126                       0               0.677                                        F             2.79 (1.39-5.57)    0.004
  Non-healthy[^b^](#tfn_003){ref-type="table-fn"}   5             99/208                        23              0.266                                        F             4.52 (1.78-11.47)   0.001
  Quality of studies                                                                                                                                                                           
  High (≥ 12)                                       6             224/133                       0               0.489                                        F             3.37 (1.58-7.21)    0.002
  Low (\< 12)                                       5             112/201                       20              0.290                                        F             3.09 (1.35-7.09)    0.008

When significant heterogeneity was found (I^2^≥ 50% or P~Q-test~ ≤ 0.1), the random-effects model (DerSimonian-Laird method) was used to pool the results; otherwise, the fixed-effects model (Mantel-Haenszel method) was applied.

Non-healthy controls included autologous controls (normal tissues adjacent to LSIL specimens), controls with benign gynecological diseases and mixed controls.

Abbreviations: N, number; LSIL, low-grade squamous intra-epithelial lesion; F, fixed-effects model.

![Forest plot for the association between *P16*^*INK4a*^ promoter hypermethylation and LSIL risk](oncotarget-08-1871-g002){#F2}

Association of *P16*^INK4a^ methylation status with HSIL risk {#s2_4}
-------------------------------------------------------------

Fifteen studies \[[@R13], [@R16], [@R17], [@R22]--[@R25], [@R27], [@R28], [@R32]--[@R35], [@R37], [@R38]\] with 587 HSIL patients and 491 controls were eligible to evaluate the association of *P16^INK4a^* methylation status with HSIL risk. A significant association was found between *P16^INK4a^* promoter hypermethylation and increased HSIL risk, with an odds ratio (OR) of 5.80 (95% CI: 3.80-8.84) and a *p* value of \< 0.001 (Figure [3](#F3){ref-type="fig"} and Table [4](#T4){ref-type="table"}). This association remained significant in all subgroups (Table [4](#T4){ref-type="table"}). We did not find significant heterogeneity in all comparisons (I^2^: 0-43%).

###### Pooled results for the association between *P16*^*INK4a*^ promoter hypermethylation and HSIL risk

  Comparisons                                        Studies (N)   Sample size (HSIL/controls)   Heterogeneity   Model [^a^](#tfn_004){ref-type="table-fn"}   Effect size                       
  -------------------------------------------------- ------------- ----------------------------- --------------- -------------------------------------------- ------------- ------------------- ----------
  Total                                              15            587/491                       18              0.253                                        F             5.80 (3.80-8.84)    \< 0.001
  Ethnicity                                                                                                                                                                                     
  Asian                                              6             198/112                       0               0.869                                        F             9.70 (3.85-24.42)   \< 0.001
  Caucasian                                          6             270/200                       38              0.374                                        F             4.61 (2.50-8.52)    \< 0.001
  Other ethnicities                                  3             119/179                       43              0.167                                        F             5.25 (2.46-11.18)   \< 0.001
  Source of controls                                                                                                                                                                            
  Healthy                                            9             393/272                       22              0.247                                        F             5.74 (3.51-9.36)    \< 0.001
  Non-healthy [^b^](#tfn_005){ref-type="table-fn"}   6             194/219                       27              0.236                                        F             5.99 (2.61-13.74)   \< 0.001
  Quality of studies                                                                                                                                                                            
  High (≥ 12)                                        7             354/211                       0               0.453                                        F             4.08 (2.16-7.73)    \< 0.001
  Low (\< 12)                                        8             233/280                       17              0.298                                        F             7.80 (4.47-13.62)   \< 0.001

When significant heterogeneity was found (I^2^≥ 50% or P~Q-test~ ≤ 0.1), the random-effects model (DerSimonian-Laird method) was used to pool the results; otherwise, the fixed-effects model (Mantel-Haenszel method) was applied.

Non-healthy controls included autologous controls (normal tissues adjacent to HSIL specimens), controls with benign gynecological diseases and mixed controls.

Abbreviations: N, number; HSIL, high-grade squamous intra-epithelial lesion; F, fixed-effects model.

![Forest plot for the association between *P16*^*INK4a*^ promoter hypermethylation and HSIL risk](oncotarget-08-1871-g003){#F3}

Association of *P16*^INK4a^ methylation status with CC risk {#s2_5}
-----------------------------------------------------------

Eighteen studies \[[@R13], [@R17], [@R19], [@R21]--[@R26], [@R30], [@R31], [@R33]--[@R38]\] with 950 CC patients and 732 controls were included to appraise the effect of *P16^INK4a^* promoter hypermethylation on CC risk. There was a significant association between *P16^INK4a^* promoter hypermethylation and increased CC risk, with an OR of 12.17 (95% CI: 5.86-25.27) and a *p* value of \< 0.001 (Figure [4](#F4){ref-type="fig"} and Table [5](#T5){ref-type="table"}). Consistent with the increasing rates of *P16^INK4a^* hypermethylation in LSIL, HSIL and CC specimens, we also found an increasing trend (*p* \< 0.001) in effects of *P16^INK4a^* promoter hypermethylation on the risk of LSIL (OR = 3.26), HSIL (OR = 5.80) and CC (OR = 12.17).

###### Pooled results for the association between *P16^INK4a^* promoter hypermethylation and CC risk

  Comparisons          Studies (N)   Sample size (CC/controls)   Heterogeneity   Model [^a^](#tfn_006){ref-type="table-fn"}   Effect size                         
  -------------------- ------------- --------------------------- --------------- -------------------------------------------- ------------- --------------------- ----------
  Total                18            950/732                     58              0.001                                        R             12.17 (5.86-25.27)    \< 0.001
  Ethnicity                                                                                                                                                       
  Asian                10            631/385                     19              0.272                                        F             18.94 (9.75-36.81)    \< 0.001
  Caucasian            5             270/200                     60              0.039                                        R             6.83 (1.98-23.55)     0.002
  Other ethnicities    3             135/179                     88              \< 0.001                                     R             9.87 (4.45-21.90)     \< 0.001
  Source of controls                                                                                                                                              
  Healthy              9             322/267                     44              0.073                                        R             13.67 (5.64-33.10)    \< 0.001
  Non-healthy          9             628/465                     69              0.001                                        R             11.32 (3.28-39.05)    \< 0.001
  Quality of studies                                                                                                                                              
  High (≥ 12)          11            583/491                     0               0.495                                        F             18.81 (10.84-32.63)   \< 0.001
  Low (\< 12)          7             427/311                     77              \< 0.001                                     R             8.83 (1.85-42.11)     0.006

When significant heterogeneity was found (I^2^≥ 50% or P~Q-test~ ≤ 0.1), the random-effects model (DerSimonian-Laird method) was used to pool the results; otherwise, the fixed-effects model (Mantel-Haenszel method) was applied.

Non-healthy controls included autologous controls (normal tissues adjacent to HSIL specimens), controls with benign gynecological diseases and mixed controls.

Abbreviations: N, number; CC, cervical cancer; R, random-effects model; F, fixed-effects model.

![Forest plot for the association between *P16^INK4a^* promoter hypermethylation and CC risk](oncotarget-08-1871-g004){#F4}

Since moderate heterogeneity was observed in the overall comparison (I^2^ = 58%), subgroup, meta-regression and Galbraith plot analyses were performed to seek the potential sources of heterogeneity. In subgroup analyses, *P16^INK4a^* promoter hypermethylation was consistently associated with increased CC risk in all subgroups (Table [5](#T5){ref-type="table"}). However, moderate heterogeneity remained in most of the subgroups, except for the subgroups involving high-quality studies (I^2^ = 0%), Asians (I^2^ = 19%) and healthy controls (I^2^ = 44%). The results of meta-regression analyses indicated that ethnicity (*p* = 0.668), source of controls (*p* = 0.678) and quality of studies (*p* = 0.289) were not major sources of heterogeneity ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The subsequent Galbraith plot depicted three outliers \[[@R13], [@R17], [@R30]\] as the potential origins of heterogeneity ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). When we excluded these three studies, the association between *P16^INK4a^* methylation status and CC risk remained significant (OR = 17.36, 95% CI: 10.61-28.42, *p* \< 0.001), followed by an effective reduction in I^2^ value from 58% to 12%.

Association of *P16*^INK4a^ methylation status with clinicopathological features of SIL/CC {#s2_6}
------------------------------------------------------------------------------------------

We first evaluated the associations of *P16^INK4a^* methylation status with several risk factors for SIL/CC, including HPV infection (Positive *vs* Negative), smoking habit (Smoker *vs* Nonsmoker) and early age at diagnosis (\< 50 *vs* ≥ 50) (Table [6](#T6){ref-type="table"}), and observed that *P16^INK4a^* promoter hypermethylation was significantly associated with smoking habit, (OR = 3.88, 95% CI: 2.13-7.08, *P* \< 0.001) (Figure [5](#F5){ref-type="fig"}), but was not correlated with HPV infection and early age at diagnosis ([Supplementary Figure 2 and 3](#SD1){ref-type="supplementary-material"}). In meta-analyses for the effects of *P16^INK4a^* methylation status on histological types (SCC *vs* AdC), clinical stages (FIGO stage: III + IV *vs* I + II) and tumor grades (Grade 2 + 3 *vs* Grade 1) in CC patients, no significant association was found (Table [6](#T6){ref-type="table"} and [Supplementary Figure 4-6](#SD1){ref-type="supplementary-material"}).

###### Pooled results for the associations between *P16^INK4a^* hypermethylation and clinicopathological features of CC/SIL

  Clinicopathological features            Studies (N)   Patients (N)   Heterogeneity   Model [^a^](#tfn_008){ref-type="table-fn"}   Effect size                      
  --------------------------------------- ------------- -------------- --------------- -------------------------------------------- ------------- ------------------ ----------
  Risk factors for SIL/CC                                                                                                                                            
  HPV infection (Positive vs Negative)    6             288            0               0.974                                        F             1.06 (0.49-2.28)   0.883
  Smoking habit (Smoker vs Nonsmoker)     3             323            0               0.751                                        F             3.88 (2.13-7.08)   \< 0.001
  Early age at diagnosis (\<50 vs ≥ 50)   3             153            0               0.380                                        F             0.91 (0.47-1.76)   0.774
  Clinical and histological data of CC                                                                                                                               
  Tumor type (SCC vs AdC)                 11            731            22              0.235                                        F             1.00 (0.68-1.48)   0.986
  FIGO stage (III + IV vs I + II)         6             470            62              0.020                                        R             1.49 (0.62-3.56)   0.368
  Tumor grade (G2 + G3 vs G1)             6             440            0               0.441                                        F             0.76 (0.46-1.24)   0.263

When significant heterogeneity was found (I^2^≥ 50% or P~Q-test~ ≤ 0.1), the random-effects model (DerSimonian-Laird method) was used to pool the results; otherwise, the fixed-effects model (Mantel-Haenszel method) was applied.

Abbreviations: N, number; CC, cervical cancer; SCC, squamous cell carcinoma; AdC, adenocarcinoma; SIL, squamous intra-epithelial lesion; F, fixed-effects model ; R,random-effects model.

![Forest plot for the association between *P16^INK4a^* promoter hypermethylation and smoking habit](oncotarget-08-1871-g005){#F5}

Evidence grading {#s2_7}
----------------

Because all eligible studies were observational, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process for all comparisons began as "low quality" \[[@R40]\]. For the comparisons of CC risk, HPV infection, early age at diagnosis, tumor type and clinical stage, the quality of evidence was further downgraded to "very low quality", due to study limitations, inconsistency or imprecision ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

Sensitivity analyses for assessing the stability of pooled results {#s2_8}
------------------------------------------------------------------

In all comparisons, sensitivity analyses by sequentially removing each study did not significantly change the pooled results, suggesting the stability of our meta-analyses ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"})

Analyses for publication bias {#s2_9}
-----------------------------

In all comparisons, funnel plots did not reveal obvious asymmetry ([Supplementary Figure 8](#SD1){ref-type="supplementary-material"}). These observations, combined with the results of Egger\'s test (*p*~Egger~ \> 0.05 for all comparisons), suggested that no significant publication bias was found.

DISCUSSION {#s3}
==========

Previous studies have long aimed to seek methylation biomarkers associated with diagnosis, progression or prognosis of cervical neoplasia. Particularly, a bi-marker panel consisting of CADM1-M18 and MAL-M1 has been considered as a stable triage tool, which could be equally discriminatory for CIN3^+^ as cytology or cytology with HPV16/18 genotyping in HPV-positive women \[[@R41]\]. In contrast, although *P16^INK4a^* promoter hypermethylation has been linked to CC and SIL, the relatively small sample size of independent studies led to inconsistent results and a broad range of hypermethylation rates in cancer tissues. In this meta-analysis, on the basis of data from over 3000 subjects, we found that the hypermethylation rates in LSIL, HSIL and CC specimens were gradually increased, resulting in a growing trend in effects of *P16^INK4a^* hypermethylation on susceptibility to LSIL, HSIL and CC. These results, combined with the previous epidemiological evidence that *P16^INK4a^* hypermethylation was correlated with the progression of LSIL to HSIL \[[@R39], [@R42]\], suggest that *P16^INK4a^* promoter hypermethylation may be an epigenetic marker for the progression of cervical carcinogenesis. Hence, detecting *P16^INK4a^* hypermethylation may help clinicians to determine whether patients with cervical neoplasia are in disease regression, persistence or progression. Especially in patients with an initial diagnosis of LSIL, once *P16^INK4a^* hypermethylation is found, more effective clinical management for these patients are encouraged to conduct.

However, the existing evidence provides limited information on the prognostic value of *P16^INK4a^* hypermethylation in cervical neoplasia. In a case-series study from China, Yang et al. found no significant association between *P16^INK4a^* hypermethylation and overall survival \[[@R29]\]. In contrast, Blanco-Luquin et al. suggested that *P16^INK4a^* hypermethylation was correlated with improved disease-free survival \[[@R38]\]. Considering that these two studies involved relatively small sample sizes and inconsistent follow-up times, better designed studies are required to address this issue.

The interaction of *P16^INK4a^* hypermethylation with HPV infection is controversial in various HPV-related cancers. For HPV-related oral and oropharyngeal cancer (OSCC) \[[@R43]\], Schlecht et al. found four *P16^INK4a^*-specific CPG loci associated with HPV infection in OSCC tissues \[[@R44]\], while another study from Chile failed to replicate this association \[[@R45]\]. For cervical carcinoma, previous functional studies have suggested that *P16^INK4a^* promoter hypermethylation mainly occurred at early cervical tumor cell populations without HPV\'s E7 transcription \[[@R46]\]. In this meta-analysis, HPV infection was not associated with *P16^INK4a^* hypermethylation in patients with SIL/CC. *P16^INK4a^* hypermethylation was associated with a 3.26-fold increased risk of LSIL, suggesting the effect of *P16^INK4a^* hypermethylation on early stage of cervical oncogenesis. All these findings may suggest that *P16^INK4a^* hypermethylation is an early event in cervical carcinogenesis, independent of HPV infection,.

In this meta-analysis, smoking habit was associated with increased *P16^INK4a^* hypermethylation rates in patients with SIL/CC. The correlation between smoking habit and *P16^INK4a^* hypermethylation has been revealed in several cancers, including non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC) \[[@R47], [@R48]\]. In a longitudinal study, Ma et al. \[[@R49]\] reported that smoking initiation was associated with a 3.76-fold increased risk of the appearance of *P16^INK4a^* hypermethylation in normal cervical smears, providing direct evidence for the relationship between smoke exposure and subsequent acquisition of *P16^INK4a^* hypermethylation in cervix. As a well known risk factor for CC \[[@R50]\], exposure to tobacco smoke, or to its key ingredients (such as nicotine or its derivative), is followed by overexpression of DNA methyltransferases 1, 3A or 3B \[[@R51], [@R52]\], which has been reported to cause hypermethylation of *P16^INK4a^* promoter in mice and cancer patients \[[@R53]\]. Considering that our pooled results were based on the data from relatively few studies, more studies with large sample size are required to repeat this finding.

Moderate heterogeneity was found in our meta-analysis for the association between *P16^INK4a^* hypermethylation and CC risk. Therefore, the results were first pooled by using the random-effects model, which cautiously estimates the study weights after accounting for the inter-study differences \[[@R54]\]. Then, by depicting the Galbraith plot, we found that three studies might be the major contributors to the existence of heterogeneity \[[@R13], [@R17], [@R30]\]. Notably, the hypermethylation rates of CC tissues enormously varied across these three studies (from 5% \[[@R17]\] to 23% \[[@R30]\] and to 95% \[[@R13]\]), suggesting the existence of inter-study differences. By appraising these three studies using our quality scoring system, we found some common flaws for these studies, including lack of biospecimen information \[[@R13], [@R17], [@R30]\], lack of information on conventional risk factors \[[@R17], [@R30]\], and lack of quality controls for methylation detection \[[@R13], [@R17]\]. Otherwise, two of three studies collected non-healthy samples (autologous tissues and samples with atypical squamous cells) as their controls \[[@R17], [@R30]\]. All these issues may lead to the heterogeneous results. Thus, to increase the stability of results, subsequent association analyses for *P16^INK4a^* hypermethylation and CC risk should collect healthy controls, and provide adequate information on related confounding factors.

The following limitations merit consideration. First, most of included studies used the MSP method to detect *P16^INK4a^* methylation status. As a qualitative method, MSP mainly relies on primer designs to guarantee its accuracy \[[@R55]\]. However, the included studies applied different primers to detect methylation status, causing the potential bias that the promoter regions detected by MSP might not always be uniform. Second, lack of clinical data for each participant limited our ability to adjust for other covariates, such as age at primiparity and menopausal status. Finally, most of included studies adopted case-control or case-only design. This might lead to some selection bias due to inherent drawback of retrospective studies. Therefore, large prospective studies should be carried out with consistent primer designs, quantitative methylation analyses and multiple clinical data.

In this meta-analysis, *P16^INK4a^* hypermethylation rates showed an increasing trend from LSIL to HSIL and ultimately to CC, causing the increasing effects of *P16^INK4a^* hypermethylation on susceptibility to LSIL, HSIL and CC. Moreover, *P16^INK4a^* hypermethylation was also correlated with smoking habit in patients with CC/SIL. Future studies are warranted to repeat these findings and elucidate the underlying mechanism.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

This meta-analysis was reported based on the PRISMA statement \[[@R56]\]. Electronic databases, including Pubmed, EMBASE and Web of Science (up to April 19, 2016), were searched by using the combinations of following terms: (*P16^INK4a^* or *P16* or *CDKN2A*) and (methylation or promoter methylation or DNA methylation) and (cervical cancer/cervical tumor/cervical neoplasia or SIL/LSIL/HSIL/or cervical dysplasia/CIN/CIS). Reference lists in reviews and retrieved articles were also checked for other relevant studies.

Eligibility criteria {#s4_2}
--------------------

Eligible studies were required to meet the following criteria: (1) an observational design (cohort, case-control, case-only or cross-sectional studies); (2) studies assessing the associations of *P16^INK4a^* methylation status with LSIL, HSIL, CC or their clinicopathological features; (3) studies with sufficient data to calculate the hypermethylation rates, ORs and their 95% CI; (4) written in English.

Exclusion criteria were as follows: (1) reviews, letters, abstracts and case reports; (2) reports with insufficient data; (3) studies regarding *in vitro* or *ex vivo* experiments; (4) family-based studies; (5) studies focusing on benign gynecological diseases. For duplicated data, only the most recent or detailed data set was selected.

Data extraction {#s4_3}
---------------

According to a predefined data collection form, data extraction was carried out by two independent authors (XBW and YDH), with any discrepancies resolved by consensus. The following information for eligible studies was collected: the first author\'s name, publication year, study design, ethnicity (country), involved diseases (LSIL, HSIL or CC) or their clinicopathological features (tumor type, clinical stage and tumor grade; age at diagnosis, smoking habit and HPV status), sample size, methods for methylation detection, sample materials, source of controls, and quality of studies.

Quality assessment of eligible studies {#s4_4}
--------------------------------------

According to a predefined system derived from the REMARK \[[@R57], [@R58]\] and BRISQ \[[@R59]\] guidelines, the quality of eligible studies was appraised by two independent authors (NHC and SZ). This quality scoring system involved 18 items, allowing for assessment of study design, study population, biospecimen information, methylation detection, clinicopathological features and results analysis ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). Studies that reported at least 12 items were considered as high-quality studies.

Evidence grading {#s4_5}
----------------

Once data synthesis was complete, we used the GRADE process to rate the quality of evidence for each comparison as high, moderate, low or very low \[[@R40]\]. Each rating was mainly based on 8 factors, involving study limitations, inconsistency, indirectness, imprecision, reporting bias, magnitude of effect, dose-response gradient and handling of potential confounders \[[@R40]\] (appraised by XBW and NHC).

Statistical Methods {#s4_6}
-------------------

The *P16^INK4a^* hypermethylation rates in LSIL, HSIL and CC specimens were estimated using the inverse variance method \[[@R60]\]. Pooled ORs and their 95% CIs were calculated to assess the associations of *P16^INK4a^* methylation status with LSIL, HSIL, CC and their clinicopathological features. The heterogeneity across the included studies was evaluated by the χ^2^-based Q-test and I^2^ statistic. I^2^ values of 25%, 50% and 75% were set as the cutoff values for mild, moderate and extensive heterogeneity, respectively \[[@R61]\]. When significant heterogeneity was found (I^2^ ≥ 50% or *P*~Q-test~ ≤ 0.1), the random-effects model (DerSimonian-Laird method) was used to pool the results; otherwise, the fixed-effects model (Mantel-Haenszel method) was applied. To further seek the potential sources of heterogeneity, meta-regression and subgroup analyses were performed based on ethnicity, source of controls and quality of studies. Then, a Galbraith plot was depicted to visualize the contribution of individual studies to the overall heterogeneity. To further appraise the stability of the pooled results, sensitivity analyses were performed by sequentially omitting each study or removing the outliers depicted by the Galbraith plot \[[@R62]\]. Publication bias was assessed qualitatively by funnel plots and quantitatively by the Egger\'s test \[[@R63]\]. An asymmetric funnel plot and *P*~Egger~ ≤ 0.05 suggested the existence of publication bias. All the above analyses were conducted by RevMan 5.2 (The Nordic Cochrane Centre, The Cochrane Collaboration) and STATA 12.0 (Stata, College, TX, USA).

SUPPLEMENTARY MATERIAL, SUPPLEMENTARY TABLES {#s5}
============================================
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